Imagine blood as a glue that helps stop leaks in your body, but some people have a 'dissolver' protein that breaks that glue down too fast. This system acts like a specialized coffee filter for plasma, removing that dissolver protein before it enters the patient. This makes the blood clot much faster, stopping dangerous bleeding more effectively.
Massive bleeding is a leading cause of preventable death, but current treatments rely on blood products that are in short supply and expensive drugs that increase the economic burden on healthcare systems.
A disposable filtration system (ClearPlasma) and the industrial molds required to mass-produce the kits.
If you are a hospital dealing with critical blood shortages and high costs of bleeding drugs — this project developed a filtration kit that can reduce the number of plasma units required by up to 45%. This lowers the economic burden of treating patients with massive bleeding.
If you are a manufacturer dealing with the need for high-volume disposable kits — this project developed a mold for mass-producing filtration kits. This allows for the scaling of a product targeting a global blood transfusion market valued at €6.34 billion.
If you are a trauma center dealing with preventable deaths from hemorrhage — this project developed ClearPlasma to improve coagulation properties. It provides a new therapeutic modality to stop bleeding faster in patients, such as those with upper gastrointestinal bleeding.
Based on available project data, specific pricing for the ClearPlasma kit is not provided, though it is noted to reduce the economic burden by decreasing the need for high-cost drugs and blood units.
Yes, the project specifically aimed to generate a mold capable of producing ClearPlasma kits in high volumes.
Based on available project data, the project is led by PLAS-FREE LTD, but specific patent or licensing terms are not detailed in the report.
The project focused on conducting clinical studies and preparing a technical file to achieve the CE mark for the European market.
The project period was from 2022-02-01 to 2023-07-31, with the goal of using clinical results to submit for the CE mark.
The project is led by a single partner, PLAS-FREE LTD, an Israeli SME. With a 100% industry ratio and no university or research institute partners, the consortium is lean and focused entirely on commercialization and clinical validation rather than basic research.
Contact PLAS-FREE LTD in Israel regarding CE mark status and clinical trial results.
Contact us to find similar blood-filtration technologies for clinical application.
